Compare Infosys Limited (INFY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Organon & Co. Common Stock — how do they compare? Infosys Limited trades at $11.7 (market cap $44.92B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Infosys Limited is far larger — about 12.4× Organon & Co. Common Stock's market cap, and Infosys Limited pays the higher dividend (4.59%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Organon & Co. Common Stock for 0 Days on average.
| INFY | OGN | |
|---|---|---|
Market Cap | $44.92B | $3.62B |
Volume | 25,564,570 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $20.22 | $13.81 |
52-Week Low | $10.49 | $5.70 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $42.66B | $11.04B |
Dividend Yield | 4.59% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal driven by oversold RSI conditions. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations. Revenue for 2025 was $19.28B, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro, positioning the firm for innovation-driven growth.
The outlook is cautiously optimistic, supported by solid profitability and strategic partnerships, but tempered by a mixed analyst consensus and potential net cash flow decline in 2026. Key risks include competitive pressures in IT services and macroeconomic sensitivity. The consensus price target of $11.48 suggests limited near-term upside from current levels.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
